Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P78380
UPID:
OLR1_HUMAN
Alternative names:
C-type lectin domain family 8 member A; Lectin-like oxidized LDL receptor 1; Lectin-type oxidized LDL receptor 1
Alternative UPACC:
P78380; A8K7V9; B4DI48; G3V1I4; Q2PP00; Q7Z484
Background:
Oxidized low-density lipoprotein receptor 1 (OxLDL receptor 1), also known as Lectin-like oxidized LDL receptor 1, plays a crucial role in atherosclerosis by mediating the recognition, internalization, and degradation of oxidatively modified LDL. It triggers a cascade of pro-inflammatory responses and is involved in antigen cross-presentation, leukocyte adhesion, and recognition of various pathogens.
Therapeutic significance:
Understanding the role of Oxidized low-density lipoprotein receptor 1 could open doors to potential therapeutic strategies.